MRPS33 Antibody

What is MRPS33 and what is its biological significance?

MRPS33 (mitochondrial ribosomal protein S33), also known as PTD003, is a 106 amino acid protein that localizes to the mitochondrion where it functions as a component of the 28S ribosomal subunit . This protein works in conjunction with other mitochondrial ribosomal proteins (MRPs) to mediate protein synthesis within mitochondria. The gene encoding MRPS33 maps to human chromosome 7, which houses over 1,000 genes and comprises nearly 5% of the human genome . MRPS33 has a calculated molecular weight of approximately 12-13 kDa and plays a critical role in mitochondrial function through its participation in the translation machinery .

What applications are MRPS33 antibodies suitable for?

Based on current literature and commercial antibody specifications, MRPS33 antibodies have been validated for multiple research applications:

Researchers should note that optimal dilutions may vary depending on specific experimental conditions and antibody lot .

How should I select the appropriate MRPS33 antibody for my experiment?

When selecting an MRPS33 antibody, consider these critical factors:

• Target epitope: Different antibodies target specific amino acid regions (e.g., AA 51-100, AA 72-100). For example, ABIN1535027 targets AA 51-100, while ABIN2584663 targets AA 72-100 .

• Species reactivity: Most commercially available MRPS33 antibodies react with human, mouse, and rat samples, but cross-reactivity varies. Some antibodies like those listed in search result show extended reactivity with dog, guinea pig, horse, and chicken samples.

• Application compatibility: Ensure the antibody has been validated for your specific application. For instance, HPA030425 is optimized for immunohistochemistry applications .

• Clonality: Most available MRPS33 antibodies are polyclonal rabbit antibodies, which offer good sensitivity but may have batch-to-batch variation .

• Validation data: Review available validation images and published literature demonstrating successful use of the antibody .

What are the optimal conditions for Western blot detection of MRPS33?

For optimal Western blot detection of MRPS33:

• Sample preparation: Prepare cell or tissue lysates in a buffer containing protease inhibitors to prevent degradation of MRPS33 protein.

• Gel selection: Use 12-15% SDS-PAGE gels due to the small size of MRPS33 (approximately 12-13 kDa).

• Transfer conditions: Use semi-dry or wet transfer with PVDF membrane (0.2 μm pore size recommended for small proteins).

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Dilute MRPS33 antibody (e.g., A29186) at 1:1000-1:2000 in blocking buffer and incubate overnight at 4°C .

• Secondary antibody: Use HRP-conjugated anti-rabbit IgG at 1:5000-1:10000 dilution.

• Detection: Standard ECL systems are typically sufficient for visualization.

• Expected band: Look for a distinct band at ~12-13 kDa. Non-specific bands may appear in some tissue types .

What fixation and staining protocols work best for MRPS33 immunohistochemistry?

For optimal immunohistochemical detection of MRPS33:

• Fixation: 4% paraformaldehyde (PFA) in PBS for 20 minutes is recommended for cell preparations . For tissue sections, standard formalin fixation and paraffin embedding protocols work well.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes is typically effective.

• Permeabilization: 0.2% Triton X-100 in PBS for 5 minutes for cellular preparations .

• Blocking: 20% FBS in PBS for 30 minutes .

• Primary antibody: HPA030425 at 1:20-1:50 dilution or A96631 at 1:50-1:100 dilution .

• Secondary antibody: Appropriate species-specific detection system (e.g., anti-rabbit AlexaFluor-488 at 1:1000) .

• Mounting: Use appropriate mounting medium with DAPI for nuclear counterstaining.

• Expected pattern: Mitochondrial/cytoplasmic punctate staining consistent with the subcellular localization of MRPS33 .

How can MRPS33 antibodies be utilized in co-immunoprecipitation experiments?

For successful co-immunoprecipitation (co-IP) of MRPS33 and its interaction partners:

• Lysis conditions: Use a mild, non-denaturing lysis buffer containing 1% NP-40 or 0.1% Triton X-100, 150mM NaCl, and protease inhibitors.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody binding: Incubate 500 μg of soluble protein extract with 30 μl Dynal magnetic beads coated with 1 μg of MRPS33 antibody .

• Incubation: Rotate end-to-end for 2 hours at 4°C .

• Controls: Include appropriate controls such as IgG control, input sample, and where possible, competition with specific peptides (e.g., MRPS33 peptide conjugated to a His Tag at 2 μg) .

• Washing: Perform 6 washes with buffer containing 0.1% Triton X-100 to remove non-specific interactions .

• Elution: Elute with Laemmli buffer for SDS-PAGE analysis .

• Analysis: Western blot or mass spectrometry to identify interaction partners.

This approach can identify novel interaction partners of MRPS33 and elucidate its role in mitochondrial ribosome assembly and function.

What strategies can be employed to study MRPS33 in mitochondrial ribosomal complexes?

To investigate MRPS33 in the context of mitochondrial ribosomal complexes:

• Subcellular fractionation: Isolate mitochondria using differential centrifugation followed by density gradient purification.

• Ribosome isolation: Extract mitochondrial ribosomes using sucrose gradient centrifugation.

• Immunoprecipitation approach:

  • Use antibodies against known mitochondrial ribosomal proteins (e.g., MRPL40) to pull down ribosomal complexes .

  • Perform Western blot analysis with MRPS33 antibodies to confirm association.

  • For competition controls, use MRPS33 peptides to validate specificity .

• Protein crosslinking: Apply reversible crosslinking agents before lysis to preserve transient interactions.

• Blue Native PAGE: Analyze intact ribosomal complexes and detect MRPS33 by subsequent immunoblotting.

• Proximity labeling: Use BioID or APEX2 fused to MRPS33 to identify proteins in close proximity within the ribosomal complex.

• Cryo-EM analysis: For structural studies of mitochondrial ribosomes, using antibodies for validation of MRPS33 positioning.

This multi-faceted approach provides insights into MRPS33's structural and functional relationships within the mitochondrial translation machinery.

How can MRPS33 expression be accurately quantified in disease models?

For precise quantification of MRPS33 expression in disease models:

• Western blotting quantification:

  • Use validated MRPS33 antibodies (e.g., A29186) at optimized dilutions .

  • Include loading controls specific for mitochondrial proteins (e.g., VDAC, COX IV).

  • Perform densitometric analysis with appropriate normalization.

• qRT-PCR:

  • Design primers specific to MRPS33 mRNA.

  • Normalize to stable reference genes appropriate for the tissue/condition being studied.

  • Validate primer efficiency and specificity.

• Immunohistochemical quantification:

  • Use standardized staining protocols with HPA030425 (1:20-1:50) .

  • Employ digital pathology tools for unbiased quantification.

  • Score based on staining intensity and percentage of positive cells.

• Flow cytometry:

  • Use FITC-conjugated MRPS33 antibodies for intracellular staining .

  • Include appropriate isotype controls.

  • Quantify mean fluorescence intensity across cell populations.

• Proteomics approach:

  • Targeted mass spectrometry using unique MRPS33 peptides.

  • Include appropriate internal standards for absolute quantification.

This comprehensive approach enables robust comparison of MRPS33 expression across different disease states and experimental conditions.

What are common issues when working with MRPS33 antibodies and how can they be resolved?

For optimal results with MRPS33 detection, researchers should perform preliminary validation experiments to determine the optimal conditions for their specific experimental system .

How can I validate the specificity of my MRPS33 antibody?

To validate MRPS33 antibody specificity:

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide (e.g., synthetic peptide derived from MRPS33 AA 51-100) .

  • Run parallel assays with and without peptide competition.

  • Specific signals should be diminished or eliminated in the presence of the peptide.

• Knockout/knockdown controls:

  • Use CRISPR/Cas9 to generate MRPS33 knockout cell lines.

  • Alternatively, use siRNA or shRNA to knock down MRPS33 expression.

  • Compare antibody reactivity between wild-type and knockout/knockdown samples.

• Overexpression validation:

  • Transfect cells with tagged MRPS33 expression constructs.

  • Perform parallel detection with MRPS33 antibody and tag-specific antibody.

  • Signals should co-localize in overexpressing cells.

• Cross-species reactivity:

  • Test antibody on samples from multiple species with known sequence homology.

  • Signal intensity should correlate with sequence conservation.

• Mass spectrometry validation:

  • Perform immunoprecipitation with the MRPS33 antibody.

  • Analyze immunoprecipitated proteins by mass spectrometry.

  • Confirm presence of MRPS33 and assess potential cross-reactivity.

These validation methods ensure that experimental results using MRPS33 antibodies are reliable and reproducible .

How can MRPS33 antibodies be applied in studying mitochondrial dysfunction in neurodegenerative diseases?

For investigating MRPS33 in neurodegenerative disease contexts:

• Multi-label immunofluorescence:

  • Co-stain with MRPS33 antibodies and markers of mitochondrial health (e.g., MitoTracker, TOMM20).

  • Include neural cell type-specific markers to assess cell type-specific alterations.

  • Use rabbit anti-MRPS33 (1:200) and appropriate fluorophore-conjugated secondary antibodies (e.g., anti-rabbit AlexaFluor-488 at 1:1000) .

• Brain tissue analysis:

  • Perform immunohistochemistry on post-mortem brain tissues from neurodegenerative disease patients.

  • Use HPA030425 at 1:20-1:50 dilution with appropriate antigen retrieval .

  • Compare MRPS33 staining patterns between disease and control tissues.

• Patient-derived models:

  • Generate induced neurons (iNs) or induced pluripotent stem cell (iPSC)-derived neurons from patients.

  • Assess MRPS33 expression and localization using validated antibodies.

  • Correlate with mitochondrial translation efficiency and function.

• Proximity ligation assay:

  • Detect and quantify interactions between MRPS33 and other mitochondrial proteins.

  • Identify disease-specific alterations in protein-protein interactions.

• Super-resolution microscopy:

  • Employ techniques like STED or STORM with MRPS33 antibodies.

  • Visualize nanoscale changes in mitochondrial ribosome structure and distribution.

These approaches can reveal alterations in mitochondrial translation machinery that may contribute to neurodegenerative disease pathogenesis.

What techniques can be used to study MRPS33 post-translational modifications?

To investigate post-translational modifications (PTMs) of MRPS33:

• Phosphorylation analysis:

  • Use phospho-specific antibodies if available, or general phospho-serine/threonine/tyrosine antibodies after MRPS33 immunoprecipitation.

  • Employ Phos-tag SDS-PAGE to resolve phosphorylated species.

  • Validate with phosphatase treatment of samples.

• Mass spectrometry approaches:

  • Immunoprecipitate MRPS33 using validated antibodies .

  • Perform LC-MS/MS analysis to identify PTM sites.

  • Use targeted methods (MRM/PRM) for specific PTM quantification.

• 2D gel electrophoresis:

  • Separate proteins by isoelectric point and molecular weight.

  • Perform Western blotting with MRPS33 antibodies.

  • Multiple spots may indicate different PTM states.

• Site-directed mutagenesis:

  • Generate mutants at predicted PTM sites.

  • Compare antibody recognition patterns between wild-type and mutant proteins.

• PTM-specific enrichment:

  • Use TiO₂ for phosphopeptide enrichment.

  • Apply ubiquitin-affinity resins for ubiquitination studies.

  • Perform lectin chromatography for glycosylation analysis.

Understanding MRPS33 PTMs may provide insights into regulatory mechanisms controlling mitochondrial ribosome assembly and function in different cellular states.

How can MRPS33 antibodies contribute to understanding mitochondrial translation in cancer research?

For investigating MRPS33 in cancer research contexts:

• Tissue microarray analysis:

  • Screen multiple cancer types using MRPS33 antibodies (HPA030425 at 1:20-1:50) .

  • Correlate expression patterns with clinical outcomes and cancer subtypes.

  • Validated in human lung carcinoma tissue using immunohistochemical analysis .

• Metabolic reprogramming studies:

  • Investigate MRPS33 expression in relation to the Warburg effect and mitochondrial function.

  • Correlate with markers of oxidative phosphorylation vs. glycolysis.

  • Use multi-parameter flow cytometry with MRPS33 antibodies .

• Drug response prediction:

  • Assess MRPS33 expression before and after treatment with mitochondria-targeting compounds.

  • Determine if MRPS33 levels predict sensitivity to specific therapeutics.

• Cancer stem cell analysis:

  • Compare MRPS33 expression between cancer stem cells and differentiated tumor cells.

  • Investigate the role of mitochondrial translation in maintaining stemness properties.

• Mitochondrial heteroplasmy investigation:

  • Use MRPS33 antibodies to assess mitochondrial translation capacity in cells with varying levels of mitochondrial DNA mutations.

  • Correlate with cancer progression and metastatic potential.

These applications can reveal how alterations in mitochondrial translation machinery contribute to cancer development, progression, and therapeutic response.